Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 3/20 | 0.49 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | DCTPP1 | Q9H773 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12497001 | 0.91 | HSD17B1 (0.49) | HSD17B1HSD17B2CYP3A4CYP2C9KDM4E | |
| SCHEMBL12937562 | 0.82 | SNCA (0.51) | HSD17B1HSD17B2CYP3A4CYP2C9KDM4E | |
| SCHEMBL12937546 | 0.82 | SNCA (0.51) | HSD17B1HSD17B2KDM4EDCTPP1MEN1 | |
| SCHEMBL12937524 | 0.81 | KDM4E (0.53) | CYP3A4CYP2C9KDM4EDCTPP1MEN1 | |
| SCHEMBL12937483 | 0.81 | PDE4A (0.44) | HSD17B1HSD17B2CYP3A4CYP2C9MEN1 | |
| SCHEMBL12682345 | 0.77 | SNCA (0.54) | CYP3A4CYP2C9KDM4EDCTPP1MEN1 | |
| SCHEMBL12498097 | 0.77 | SNCA (0.54) | CYP3A4CYP2C9KDM4EDCTPP1MEN1 | |
| SCHEMBL19508309 | 0.77 | HSD17B1 (0.53) | HSD17B1HSD17B2CYP3A4CYP2C9KDM4E | |
| SCHEMBL12937489 | 0.75 | SNCA (0.47) | KDM4EDCTPP1MEN1KMT2ATSHR | |
| SCHEMBL12497223 | 0.75 | SNCA (0.55) | CYP3A4CYP2C9KDM4ETSHRPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180002298-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PROTAMED INC (US) | 2018-01-04 | — | — | US | disclosed |
| US-20170022174-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PROTAMED INC (US) | 2017-01-26 | — | — | US | disclosed |
| US-9334251-B2 | Compounds for the treatment of neurodegenerative diseases | PROTAMED, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150274681-A1 | Compounds for the treatment of Neurodegenerative Diseases | PROTEOTECH INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-9085549-B2 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC (US) | 2015-07-21 | — | — | US | disclosed |
| US-20150011604-A1 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8865754-B2 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20120251448-A1 | Compounds for Use in the Detection of Neurodegenerative Diseases | AVID RADIOPHARMACEUTICALS, INC. | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274681-A1 | Compounds for the treatment of Neurodegenerative Diseases | PSEN1, PSEN2, GRN | HSD17B1 1374/4885HSD17B2 1962/4885CYP3A4 4813/4885 |
| US-20180002298-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PSEN1, PSEN2, GRN | HSD17B1 1374/4885HSD17B2 1962/4885CYP3A4 4813/4885 |
| US-20150011604-A1 | Compounds for the treatment of neurodegenerative diseases | SNCA, MAPT, PARK7 | HSD17B1 3806/4885HSD17B2 3827/4885CYP3A4 4520/4885 |
| US-20120251448-A1 | Compounds for Use in the Detection of Neurodegenerative Diseases | SNCA, PARK7, NLN | HSD17B1 4489/4885HSD17B2 4496/4885CYP3A4 4719/4885 |
| US-20170022174-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PSEN1, PSEN2, GRN | HSD17B1 1374/4885HSD17B2 1962/4885CYP3A4 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.